These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30077902)

  • 21. Structural basis for specificity of TGFβ family receptor small molecule inhibitors.
    Ogunjimi AA; Zeqiraj E; Ceccarelli DF; Sicheri F; Wrana JL; David L
    Cell Signal; 2012 Feb; 24(2):476-483. PubMed ID: 21983015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of Toxoplasma gondii virulence factor ROP18 competitive inhibitors by virtual screening.
    Yin K; Zhao G; Xu C; Qiu X; Wen B; Sun H; Liu G; Liu Y; Zhao Q; Wei Q; Huang B; Yan G; Cao J
    Parasit Vectors; 2019 Mar; 12(1):98. PubMed ID: 30867024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
    Kaur M; Silakari O
    J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacophore generation, atom-based 3D-QSAR and molecular dynamics simulation analyses of pyridine-3-carboxamide-6-yl-urea analogues as potential gyrase B inhibitors.
    Azam MA; Thathan J
    SAR QSAR Environ Res; 2017 Apr; 28(4):275-296. PubMed ID: 28399673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-guided Design and Optimization of small Molecules as Pancreatic Lipase Inhibitors using Pharmacophore, 3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation Studies.
    Modanwal S; Mulpuru V; Mishra N
    Curr Comput Aided Drug Des; 2023; 19(4):258-277. PubMed ID: 36597611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
    Lee YH; Yi GS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
    Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
    J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
    Liu X; Yu M; Chen Y; Zhang J
    Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3D-QSAR and docking studies on transforming growth factor (TGF)-beta receptor 1 antagonists.
    Geldenhuys WJ; Nakamura H
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1918-23. PubMed ID: 20176484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel small molecule TGF-β antagonists using structure-based drug design.
    Wang H; Sessions RB; Prime SS; Shoemark DK; Allen SJ; Hong W; Narayanan S; Paterson IC
    J Comput Aided Mol Des; 2013 Apr; 27(4):365-72. PubMed ID: 23625024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
    Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
    Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.
    James N; Shanthi V; Ramanathan K
    Appl Biochem Biotechnol; 2018 May; 185(1):289-315. PubMed ID: 29134510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
    Kumari M; Chandra S; Tiwari N; Subbarao N
    BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
    Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
    Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico studies on the interaction between bioactive ligands and ALK5, a biological target related to the cancer treatment.
    Almeida MO; Trossini GH; Maltarollo VG; Silva Dda C; Honorio KM
    J Biomol Struct Dyn; 2016 Sep; 34(9):2045-53. PubMed ID: 26524124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies.
    Dahiya L; Mahapatra MK; Kaur R; Kumar V; Kumar M
    Comb Chem High Throughput Screen; 2017; 20(4):310-320. PubMed ID: 28302016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QSAR studies on imidazopyrazine derivatives as Aurora A kinase inhibitors.
    Leng Y; Lu T; Yuan HL; Liu HC; Lu S; Zhang WW; Jiang YL; Chen YD
    SAR QSAR Environ Res; 2012 Oct; 23(7-8):705-30. PubMed ID: 22971111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
    Qiu Y; Zhou L; Hu Y; Bao Y
    J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.